Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Supplementary Table S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Home
Publications
Supplementary Table S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Table S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Authors:
DK
Di Kang
Di Kang
YW
Yanping Wang
Yanping Wang
YL
Yiwei Lin
Yiwei Lin
WM
Wen Wee Ma
Wen Wee Ma
DM
Daniel Morgensztern
Daniel Morgensztern
KL
Konstantinos Leventakos
Konstantinos Leventakos
CB
Chao Bi
Chao Bi
YD
Yuli Ding
Yuli Ding
JX
Jing Xiong
Jing Xiong
MY
Man Yan
Man Yan
XS
Xin Sun
Xin Sun
PW
Peng Wang
Peng Wang
See more
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Open Access
Publisher website
Google Scholar
15 July 2025
other
Published by
American Association for Cancer Research (AACR)
DOI:
10.1158/1078-0432.29568179
Abstract
Supplementary Table S3. Representativeness of study participants.
Keywords
CLINICAL-STAGE RESEARCH
DRUG RESISTANCE
REVERSAL OF DRUG RESISTANCE
IMMUNOTHERAPY
COMBINATION IMMUNOTHERAPY
PRECLINICAL MODELS
XENOGRAFT MODELS
SMALL MOLECULE AGENTS
PHOSPHATASE INHIBITORS
Related articles
Scroll to top